A new global analysis suggests that the shingles vaccine might reduce your risk of a heart attack or stroke by nearly one-fifth, The Guardian reports. That’s more than just icing on the healthcare cake. It’s a compelling sign that a jab traditionally meant to stop shingles could help protect against cardiovascular events as well.
A surprising link between vaccines and heart health
Researchers compiled data from a dozen randomised trials and observational studies, assessing nearly 19 sources in total, and discovered an 18% lower risk of heart attack or stroke in adults 18 and older who received the vaccine. Among those aged 50 and above, the reduction was still solid: about 16%. These findings suggest the benefits aren’t limited to older or immunocompromised patients but extend across broader age groups.
To visualise it in human terms, that equates to about 1.2 to 2.2 fewer major cardiovascular events per 1,000 people per year. And for those vaccinated with the newer recombinant vaccine, like Shingrix, which is now standard in many countries, the protections may be even stronger, though more data is needed.
Experts warn, however, that the evidence is mostly observational, which means causation hasn’t been proven. It’s possible that healthier people are simply more likely to get vaccinated. Still, there’s a plausible explanation behind the correlation: shingles itself can trigger inflammation in blood vessels, increasing stroke and heart attack risk. By preventing both the viral infection and the associated inflammation, the vaccine could indirectly reduce cardiovascular strain.
What this means for public health, and where research goes next
This possibility turns prevention on its head. For decades, medical advice has focused on cholesterol, blood pressure, lifestyle. The idea that a viral vaccine could double as a cardiovascular shield adds a whole new dimension.
Beyond the immediate impact, it’s already having policy ripples. NHS England plans to expand eligibility for the shingles vaccine. Starting next month, immunocompromised adults aged 18 to 49 will now be eligible, a group previously excluded. Whether that is being done to reflect these cardiovascular findings or to widen protection, the timing suggests both factors are at play.
Looking further afield, there’s compelling data from South Korea showing even longer-term protection with earlier vaccines. In that study of over 1.2 million people aged 50 and older, recipients of the older live zoster jab had a 26% lower risk of heart failure, heart attacks, and stroke for up to eight years after vaccination, especially among men, younger adults under 60, and those with lifestyle risk factors.
Taken together, these studies suggest there may be a general benefit to systemic inflammation control, and that vaccines like the shingles jab could play a role in that.
But there are unanswered questions before doctors start prescribing it for heart health. Most urgently, we need clinical trials designed specifically to test cardiovascular outcomes. We also need head-to-head comparisons between the older live vaccine and Shingrix, as the latter is now more commonly used due to better effectiveness and fewer side effects in older or immune-suppressed patients.
That said, the implications are enormous. If vaccination against shingles can become part of cardiovascular prevention, the strategy scales easily. National immunisation budgets are already structured, and uptake could rise quickly with even modest messaging shifts.
Beyond the numbers, there’s a human narrative here too. Fans of preventive medicine, and anyone tired of multi-pill regimens, may find reassurance in a single vaccine delivering dual protection. For doctors, this could mean fewer heart attacks and strokes down the line. For individuals, it means a jab that does more than you bargained for.
We’re a considerable distance from calling it a heart vaccine, but it’s clear that shingles jabs might be one of the smartest tools we already have, delivering benefits well beyond a rash. If future research confirms what early data suggests, this might be one of the cleanest wins in public health: a vaccine that protects two of the most common afflictions—painful infection and heart disease—at once.